Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.) (RT2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02088203

Recruitment Status : Completed

First Posted : March 14, 2014

Last Update Posted : March 21, 2019

Sponsor:

Collaborators:

National Center for Complementary and Integrative Health (NCCIH)

Office of Dietary Supplements (ODS)

Information provided by (Responsible Party):

Jennifer C. Rood, Pennington Biomedical Research Center

Study Description

Brief Summary:

Safety and tolerability of a soy-protein Russian Tarragon complex versus a placebo.

Condition or disease	Intervention/treatment	Phase
Diabetes Prevention	Dietary Supplement: Dose 1 Dietary Supplement: Dose 2 Dietary Supplement: Dose 0 Dietary Supplement: Dose 3 Dietary Supplement: Dose 4 Dietary Supplement: Dose 5 Dietary Supplement: Dose 6	Phase 1

Show detailed description

Detailed Description:

Plants from the genus Artemisia, and specifically Artemisia dracunculus L. (Russian tarragon) have had a long history of medicinal (health) and culinary (food) use and have been reported as effective as a traditional treatments for diabetes in various parts of the world. The overall objective of this study is to conduct early human investigation and to evaluate the effect of nutritional supplementation with a well characterized extract of Artemisia dracunculus L. The primary objectives would be to evaluate safety, tolerability and effective dose in non-diabetic human subjects. Secondary objectives would assess metabolism of the extract and evaluate effects on proposed mechanisms such as insulin secretion, lipid levels and/or insulin resistance.

Single Oral Dose Evaluation

After completing a screening visit and meeting qualifications for the single oral dose evaluation, subjects will receive three single doses (two different doses of the supplement and one dose of placebo) on three separate test periods which are separated by a washout period of at least 7 days. Each testing period requires an overnight stay on the inpatient unit. The inpatient stay will be approximately 26 hours. The doses that will be used in the study are 0.3, 1, 3, 10, 20 and 30 grams plus the placebo. The supplement and the placebo will be mixed with sugar-free flavoring in water. There will be an opportunity to sample the liquid drink during the screening visit.

Screening Visit 1 (about 1 hour) - Fasting (Nothing to eat or drink other than water for at least 10 hours prior to appointment)

Sign informed consent if willing to participate
Body weight and height will be measured (body mass index will be calculated from these measures)
Blood pressure, pulse and temperature will be measured
Physical exam and ECG (electrocardiogram)
Report any medications taken over the past 3 months
Blood draw (about 2 teaspoons) to assess overall health
Taste test

ALL PROCEDURES AND VISITS LISTED BELOW WILL BE REPEATED 3 TIMES. ALL TESTING WILL BE DONE FOR EACH SINGLE DOSE TESTING PERIOD (1,2,3)

Testing Period 1: Day -3, Day 1, Day 2
7 Day Washout
Testing Period 2: Day -3, Day 1, Day 2
7 Day Washout
Testing Period 3: Day -3, Day 1, Day 2

Day -3 (about 4 hours) Fasting (Nothing to eat or drink other than water for at least 10 hours prior to appointment)

Blood pressure, pulse and temperature will be measured
An IV line will be placed in an arm vein for blood draw purposes and will remain there throughout the testing.
A blood draw (approximately 2 teaspoons) will be done before and after dosing to assess any changes in glucose or insulin.
An Oral Glucose Tolerance Test (OGTT) will be done A blood sample will be drawn from the IV line, and then the subject will drink a sugar solution consisting of 75 grams of glucose. Blood will be drawn at specific times after the drink is consumed. Each blood sample will be about 1 tablespoon. (6 tablespoons total for the test). During the IV procedure, a small amount of the subject's own blood (less than 1 teaspoon) will immediately be returned into the vein through the IV after each specimen is collected.
Adverse events and changes in medication will be assessed by the staff
Meet with staff briefly about dietary intake and weight maintenance diets

Day 1 (Inpatient Stay- 26 hours) Fasting (Nothing to eat or drink other than water for at least 10 hours prior to appointment)

Admission to the inpatient unit in the morning of the Day 1 visit. The subject will remain on the unit overnight and be discharged on Day 2.
Blood pressure, pulse and temperature will be measured.
Randomization to the study dosing scheme will occur. Randomization is like flipping a coin. The subject and the study staff will not know what dose the subject is receiving or if the subject is receiving a placebo (inactive drink).
Single dose of extract given (either the supplement or placebo). The dose will be given 2 hours prior to the start of the OGTT. The extract will be in a powder form and will be mixed with up to 8 ounces of liquid for the subject to drink.
An IV line will be placed in the arm vein for blood draw purposes and will remain there throughout the testing.
OGTT as described above (at day -3).
A blood draw (approximately 2 teaspoons) before and after dosing will be done to assess any changes in glucose or insulin. Blood draws will occur at 30, 60, 90, 120, 180, 240 minutes and 12 hours after dosing.
An ECG will be performed.
Adverse events and changes in medication will be assessed by the staff.
The subject will be asked to fast overnight until your blood work on Day 2.

Day 2 (Inpatient) Blood pressure, weight, pulse and temperature will be measured.

A physical exam will be done
A 24 hour post dose blood draw (approximately 1 teaspoon) will be done.
Study staff will schedule the next testing period if applicable and then the subject will be discharged from the inpatient unit.

Multiple Oral Dose Evaluation

After completing a screening visit and meeting qualifications for the multiple oral dose evaluation, subjects will receive three doses (two different doses of the supplement and one dose of placebo) over three separate 21-day test periods that are each separated by a washout period of at least 7 days. Each testing period involves 8 clinic visits. The doses that will be used in the study are 0.3, 1, and 30 grams plus the placebo. The supplement and the placebo will be mixed with sugar-free flavoring in water. There will be an opportunity to sample the liquid drink during the screening visit.

Screening Visit 1 (about 1 hour) - Fasting (Nothing to eat or drink other than water for at least 10 hours prior to appointment)

Sign informed consent if willing to participate
Body weight and height will be measured (body mass index will be calculated from these measures)
Blood pressure, pulse and temperature will be measured
Physical exam and ECG (electrocardiogram)
Report any medications taken over the past 3 months
Blood draw (about 2 teaspoons) and urine collection to assess overall health
Meet with dietitian about normal dietary intake
Taste test

ALL PROCEDURES AND VISITS LISTED BELOW WILL BE REPEATED 3 TIMES. ALL TESTING WILL BE DONE FOR EACH MULTIPLE DOSE TESTING PERIOD (1,2,3)

Testing Period 1: Day -3, Day 1, Day 3, Day 7, Day 10, Day 14, Day 17, Day 21
7 Day Washout
Testing Period 2: Day -3, Day 1, Day 3, Day 7, Day 10, Day 14, Day 17, Day 21
7 Day Washout
Testing Period 3: Day -3, Day 1, Day 3, Day 7, Day 10, Day 14, Day 17, Day 21

Day -3 (about 4 hours) Fasting (Nothing to eat or drink other than water for at least 10 hours prior to appointment)

Blood pressure, pulse, weight, and temperature will be measured
An IV line will be placed in an arm vein for blood draw purposes and will remain there throughout the testing.
An Oral Glucose Tolerance Test (OGTT) will be done. A blood sample will be drawn from the IV line, and then the subject will drink a sugar solution consisting of 75 grams of glucose. Blood will be drawn at specific times after the drink is consumed. Each blood sample will be about 1 tablespoon (3 tablespoons total for the test). During the IV procedure, a small amount of the subject's own blood (less than 1 teaspoon) will immediately be returned into the vein through the IV after each specimen is collected.
Females of child-bearing potential will have a urine pregnancy test
A dual-energy X-ray absorptiometry (DXA) scan will be performed using a whole-body scanner. This scan measures the amount of bone, muscle, and fat in the body. The subject will wear a hospital gown, remove all metal-containing objects, and lie down on a table with legs held together by Velcro straps. A scanner emitting low-energy X rays and a detector will pass along the body. The subject is asked to remain completely still for the duration of the 10-minute scan.
Adverse events and changes in medication will be assessed by the staff
Meet with staff to assess dietary intake since prior visit

Day 1 (about 45 minutes) Non-fasting

Blood pressure, pulse, weight, and temperature will be measured.
Randomization to the study dosing scheme will occur. Randomization is like flipping a coin. The subject and the study staff will not know what dose the subject is receiving or if the subject is receiving a placebo (inactive drink).
The first dose of extract will be given (either the supplement or placebo). The subject will be given instructions on how to take the extract at home. The extract will be in a powder form to be mixed with up to 8 ounces of liquid to drink.
Adverse events and changes in medication will be assessed by the staff.

Days 3, 10, and 17 (about 30 minutes each) Non-fasting

Blood pressure, pulse, weight, and temperature will be measured.
Compliance with extract dosing will be assessed and additional extract dispensed as needed.
Adverse events and changes in medication will be assessed by the staff.

Days 7, 14, and 21 (about 6 hours each) Fasting (Nothing to eat or drink other than water for at least 10 hours prior to appointment)

Blood pressure, pulse, weight, and temperature will be measured.
Compliance with extract dosing will be assessed and additional extract dispensed as needed (except at Day 21 when dosage is stopped).
Adverse events and changes in medication will be assessed by the staff.
Physical exam and ECG (electrocardiogram) will be performed.
An IV line will be placed in the arm vein for blood draw purposes and will remain there throughout the testing.
OGTT as described above (at Day -3).
A blood draw (approximately 3 tablespoons) before and after dosing will be done to assess any changes in glucose or insulin. Blood draws will occur at 0, 30, 60, 90, 120, 180, and 240 minutes after dosing.
Urine samples will be collected throughout the test day to measure the body's response to the daily doses of extract.
Meet with dietitian to assess food intake to assure it has not changed from normal diet.
At Day 21 only, a DXA scan will be performed as described above (at Day -3). Females of child-bearing potential will have a urine pregnancy test prior to the DXA scan.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	64 participants
Allocation:	Randomized
Intervention Model:	Crossover Assignment
Masking:	Double (Participant, Investigator)
Primary Purpose:	Prevention
Official Title:	Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.) Complex as a Dietary Supplement to Improve Carbohydrate Metabolism; Dosing, Safety and Tolerability
Actual Study Start Date :	February 2014
Actual Primary Completion Date :	May 2018
Actual Study Completion Date :	May 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Artemisia dracunculus

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Single Dose Sequence 1 Dose 1, Dose 2, Dose 0: Each subject will receive a single dose during each of three separate test periods.	Dietary Supplement: Dose 1 Russian Tarragon Nutrasorb 0.3 g Dietary Supplement: Dose 2 Russian Tarragon Nutrasorb 1 g Dietary Supplement: Dose 0 Placebo
Experimental: Single Dose Sequence 2 Dose 1, Dose 0, Dose 2: Each subject will receive a single dose during each of three separate test periods.	Dietary Supplement: Dose 1 Russian Tarragon Nutrasorb 0.3 g Dietary Supplement: Dose 2 Russian Tarragon Nutrasorb 1 g Dietary Supplement: Dose 0 Placebo
Experimental: Single Dose Sequence 3 Dose 0, Dose 1, Dose 2: Each subject will receive a single dose during each of three separate test periods.	Dietary Supplement: Dose 1 Russian Tarragon Nutrasorb 0.3 g Dietary Supplement: Dose 2 Russian Tarragon Nutrasorb 1 g Dietary Supplement: Dose 0 Placebo
Experimental: Single Dose Sequence 4 Dose 3, Dose 4, Dose 0: Each subject will receive a single dose during each of three separate test periods.	Dietary Supplement: Dose 0 Placebo Dietary Supplement: Dose 3 Russian Tarragon Nutrasorb 3 g Dietary Supplement: Dose 4 Russian Tarragon Nutrasorb 10 g
Experimental: Single Dose Sequence 5 Dose 3, Dose 0, Dose 4: Each subject will receive a single dose during each of three separate test periods.	Dietary Supplement: Dose 0 Placebo Dietary Supplement: Dose 3 Russian Tarragon Nutrasorb 3 g Dietary Supplement: Dose 4 Russian Tarragon Nutrasorb 10 g
Experimental: Single Dose Sequence 6 Dose 0, Dose 3, Dose 4: Each subject will receive a single dose during each of three separate test periods.	Dietary Supplement: Dose 0 Placebo Dietary Supplement: Dose 3 Russian Tarragon Nutrasorb 3 g Dietary Supplement: Dose 4 Russian Tarragon Nutrasorb 10 g
Experimental: Single Dose Sequence 7 Dose 5, Dose 6, Dose 0: Each subject will receive a single dose during each of three separate test periods.	Dietary Supplement: Dose 0 Placebo Dietary Supplement: Dose 5 Russian Tarragon Nutrasorb 20 g Dietary Supplement: Dose 6 Russian Tarragon Nutrasorb 30 g
Experimental: Single Dose Sequence 8 Dose 5, Dose 0, Dose 6: Each subject will receive a single dose during each of three separate test periods.	Dietary Supplement: Dose 0 Placebo Dietary Supplement: Dose 5 Russian Tarragon Nutrasorb 20 g Dietary Supplement: Dose 6 Russian Tarragon Nutrasorb 30 g
Experimental: Single Dose Sequence 9 Dose 0, Dose 5, Dose 6: Each subject will receive a single dose during each of three separate test periods.	Dietary Supplement: Dose 0 Placebo Dietary Supplement: Dose 5 Russian Tarragon Nutrasorb 20 g Dietary Supplement: Dose 6 Russian Tarragon Nutrasorb 30 g
Experimental: Multiple Dose Sequence 1 Dose 1, Dose 0, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.	Dietary Supplement: Dose 1 Russian Tarragon Nutrasorb 0.3 g Dietary Supplement: Dose 2 Russian Tarragon Nutrasorb 1 g Dietary Supplement: Dose 0 Placebo
Experimental: Multiple Dose Sequence 2 Dose 1, Dose 2, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.	Dietary Supplement: Dose 1 Russian Tarragon Nutrasorb 0.3 g Dietary Supplement: Dose 2 Russian Tarragon Nutrasorb 1 g Dietary Supplement: Dose 0 Placebo
Experimental: Multiple Dose Sequence 3 Dose 0, Dose 1, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.	Dietary Supplement: Dose 1 Russian Tarragon Nutrasorb 0.3 g Dietary Supplement: Dose 2 Russian Tarragon Nutrasorb 1 g Dietary Supplement: Dose 0 Placebo
Experimental: Multiple Dose Sequence 4 Dose 2, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.	Dietary Supplement: Dose 2 Russian Tarragon Nutrasorb 1 g Dietary Supplement: Dose 0 Placebo Dietary Supplement: Dose 6 Russian Tarragon Nutrasorb 30 g
Experimental: Multiple Dose Sequence 5 Dose 2, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.	Dietary Supplement: Dose 2 Russian Tarragon Nutrasorb 1 g Dietary Supplement: Dose 0 Placebo Dietary Supplement: Dose 6 Russian Tarragon Nutrasorb 30 g
Experimental: Multiple Dose Sequence 6 Dose 0, Dose 2, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.	Dietary Supplement: Dose 2 Russian Tarragon Nutrasorb 1 g Dietary Supplement: Dose 0 Placebo Dietary Supplement: Dose 6 Russian Tarragon Nutrasorb 30 g
Experimental: Multiple Dose Sequence 7 Dose 1, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.	Dietary Supplement: Dose 1 Russian Tarragon Nutrasorb 0.3 g Dietary Supplement: Dose 0 Placebo Dietary Supplement: Dose 6 Russian Tarragon Nutrasorb 30 g
Experimental: Multiple Dose Sequence 8 Dose 1, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.	Dietary Supplement: Dose 1 Russian Tarragon Nutrasorb 0.3 g Dietary Supplement: Dose 0 Placebo Dietary Supplement: Dose 6 Russian Tarragon Nutrasorb 30 g
Experimental: Multiple Dose Sequence 9 Dose 0, Dose 1, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.	Dietary Supplement: Dose 1 Russian Tarragon Nutrasorb 0.3 g Dietary Supplement: Dose 0 Placebo Dietary Supplement: Dose 6 Russian Tarragon Nutrasorb 30 g

Outcome Measures

Primary Outcome Measures :

Levels of bioactive components from the Russian Tarragon Nutrasorb in the blood and urine [ Time Frame: on average weekly for 3 weeks ]

Secondary Outcome Measures :

Glucose tolerance measured with an OGTT [ Time Frame: on average weekly for 3 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Are an overall healthy adult
Are male or female, ages 18-65 at time of consent
Are female and of childbearing potential, you must agree to use one of the approved contraception method [(i.e., barrier method, intrauterine and cervical devices, oral contraceptives, hormonal injections (Depo Provera®), condoms with spermicidal gel or foam, contraceptive patch (Ortho Evra), diaphragm, or abstinence)], prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the follow-up visit.
Have a BMI within the range 18.5-40 kg/m2 (this is a measure of your height to weight ratio).
Are capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Have no significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, endocrine, neurological and psychiatric disease
Have overall normal clinical laboratory tests as deemed by the physician

Exclusion Criteria:

Have a prior history of Type 1 or 2 diabetes
Are a female who is pregnant or lactating.
Are taking certain medications (these will be reviewed with you by the study staff).
Are anticipating or planning to have surgery during the study period.
Are a current smoker or have smoked within the previous 6 months.
Have had a weight change of more than 5% in the last 2 months.
Are taking prescription or over the counter medications or supplements for weight loss.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02088203

Locations

Layout table for location information

United States, Louisiana
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States, 70808

Sponsors and Collaborators

Pennington Biomedical Research Center

National Center for Complementary and Integrative Health (NCCIH)

Office of Dietary Supplements (ODS)

Investigators

Layout table for investigator information

Principal Investigator:	Jennifer C Rood, Ph.D.	Pennington Biomedical Research Center

Study Documents (Full-Text)

Documents provided by Jennifer C. Rood, Pennington Biomedical Research Center:

Study Protocol and Statistical Analysis Plan [PDF] January 26, 2017

More Information

Layout table for additonal information

Responsible Party:	Jennifer C. Rood, Principal Investigator, Pennington Biomedical Research Center
ClinicalTrials.gov Identifier:	NCT02088203
Other Study ID Numbers:	PBRC 2013-049 P50AT002776 ( U.S. NIH Grant/Contract )
First Posted:	March 14, 2014 Key Record Dates
Last Update Posted:	March 21, 2019
Last Verified:	March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Undecided

To Top